- Home
- DDS vs EXAS Comparison
DDS vs EXAS Comparison
Compare DDS & EXAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DDS
- EXAS
- Stock Information
- Founded
- DDS 1938
- EXAS 1995
- Country
- DDS United States
- EXAS United States
- Employees
- DDS N/A
- EXAS N/A
- Industry
- DDS Department/Specialty Retail Stores
- EXAS Medical Specialities
- Sector
- DDS Consumer Discretionary
- EXAS Health Care
- Exchange
- DDS Nasdaq
- EXAS Nasdaq
- Market Cap
- DDS 9.2B
- EXAS 10.6B
- IPO Year
- DDS N/A
- EXAS N/A
- Fundamental
- Price
- DDS $615.50
- EXAS $57.77
- Analyst Decision
- DDS Sell
- EXAS Strong Buy
- Analyst Count
- DDS 3
- EXAS 21
- Target Price
- DDS $394.33
- EXAS $68.05
- AVG Volume (30 Days)
- DDS 110.0K
- EXAS 2.2M
- Earning Date
- DDS 11-13-2025
- EXAS 11-04-2025
- Dividend Yield
- DDS 4.25%
- EXAS N/A
- EPS Growth
- DDS N/A
- EXAS N/A
- EPS
- DDS 36.31
- EXAS N/A
- Revenue
- DDS $6,585,750,000.00
- EXAS $2,939,949,000.00
- Revenue This Year
- DDS N/A
- EXAS $16.68
- Revenue Next Year
- DDS N/A
- EXAS $12.15
- P/E Ratio
- DDS $16.86
- EXAS N/A
- Revenue Growth
- DDS N/A
- EXAS 12.55
- 52 Week Low
- DDS $282.24
- EXAS $38.81
- 52 Week High
- DDS $637.73
- EXAS $72.83
- Technical
- Relative Strength Index (RSI)
- DDS 61.80
- EXAS 74.22
- Support Level
- DDS $605.59
- EXAS $52.88
- Resistance Level
- DDS $637.73
- EXAS $54.74
- Average True Range (ATR)
- DDS 18.60
- EXAS 1.41
- MACD
- DDS -2.61
- EXAS 0.33
- Stochastic Oscillator
- DDS 66.60
- EXAS 91.32
About DDS Dillard's Inc.
Dillard's Inc is an American fashion apparel, cosmetics, and home furnishings retailer. Its stores offer a large variety of merchandise and feature products from both national and exclusive brand sources. The company also operates a general contracting construction company, CDI Contractors. CDI Contractors' business includes constructing and remodelling stores for Dillards. The merchandise selections include exclusive brand merchandise such as Antonio Melani, Gianni Bini, Daniel Cremieux, Roundtree & Yorke, and private-label merchandise, among others. The company operates in two business segments; Retail Operations and Construction. The Retail Operations segment generates maximum revenue for the company.
About EXAS Exact Sciences Corporation
Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test is a noninvasive stool-based DNA test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It also has a pipeline of blood-based tests for molecular residual disease, colorectal cancer screening, and multicancer screening.